A proof-of-concept clinical trial assessing the safety of the coordinated undermining of
survival paths by 9 repurposed drugs combined with metronomic temozolomide (CUSP9v3 treatment
protocol) for recurrent glioblastoma
We will connect you to the doctor responsible for this trial and help you get more information.
Locations near you
Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Full eligibility criteria for NCT02770378
Ages eligible for Study
18 Years and older
Genders eligible for Study
Accepts Healthy Volunteers
Patients with a diagnosis of glioblastoma World Health Organization (WHO) grade IV
(histologically confirmed by a pathologist). Patients with prior low-grade glioma are eligible if histological transformation to WHO grade IV glioblastoma was confirmed.
Progression (according to RANO criteria) after prior radiation and temozolomide treatment
No more than 3 prior episodes of tumor progression
≥ 4 weeks between surgical resection or chemotherapy
≥ 12 weeks since last radiotherapy
Patients > 18 years of age.
Karnofsky performance status (KPS) of ≥ 70%
Stable steroid dose for ≥ 1 week
Hemoglobin ≥ 10 g/l
Absolute neutrophil count (ANC) > 10³ cells/µl
Platelet count > 100/µl
Maximum 5 years since last Pneumovax (or equivalent) and varicella vaccination
Serum creatinine, aspartat-aminotransferase (AST) and bilirubin ≤ 1.5 times the upper limit of normal (ULN)
Female patients of childbearing potential with a negative pregnancy test within 7 days of initiation of study treatment. Postmenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential.
Male and female patients of reproductive potential who agree to employ an effective method of birth control throughout the study and for up to 6 months following discontinuation of study drug. Patients must be counseled on the possibility of cryopreservation of oocytes or sperm.
Signed informed consent prior to initiation of any study procedure (must understand, voluntarily sign the informed consent form and be able to adhere to the study visit schedule and other protocol requirements).
Female patients who are pregnant or breast-feeding
Any uncontrolled/unstable medical condition except glioblastoma, including but not limited to uncontrolled/unstable hypertension, uncontrolled/unstable diabetes, uncontrolled endocrinopathies of any kind, uncontrolled/unstable psychiatric conditions
Renal failure (eGFR < 60 ml/min)
Active infection, including pneumonia as shown on X-ray
Therapeutic anticoagulation use
Prior stereotactic radiosurgery
Radiolabeled monoclonal antibody therapy unless there was unequivocal disease progression (e.g. a new lesion or biopsy-confirmed recurrence)
QT interval (QTc) < 470 msec (based on the mean value of triplicate ECGs), family or personal history of long or short QT syndrome, Brugada syndrome, or known history of QTc prolongation or Torsade de Pointes
Uncontrolled electrolyte disorders that can aggravate the effects of a QTc-prolonging drug (e.g., hypocalcemia, hypokalemia, hypomagnesemia)
History of severe hypersensitivity reaction (≥ grade 3) to any component of the investigational drugs or excipients
Unable to undergo contrast-enhanced MRI
Patients who have been treated with any investigational agent(s) within 28 days of the first day of administration of study drugs
Current active second malignancy other than non-melanoma skin cancers and post-treatment of localized prostate cancer. Patients are not considered to have a currently active malignancy if they are in complete remission for > 3 years prior to study
Known HIV infection, active Hepatitis B or C infection
Any ongoing toxicity from prior anti-cancer therapy that is > grade 1 and/or that is progressing in severity (except alopecia) and delayed recovery following last temozolomide cycle
Additional anti-cancer treatment for glioblastoma other than study drug and supportive measures (i.e. dexamethasone)
Patients refusing consent for registration, storage, and processing of individual disease characteristics, information on the course of the disease, and information obtained from the family physician and/or other physicians involved in the treatment of the patient about study participation.
All locations for NCT02770378
University of Ulm School of Medicine
Ulm, Baden-Württemberg, Germany, 89081
View full eligibility
Tris trial is registered with FDA with number: NCT02770378. The sponsor of the trial is University of Ulm and it is looking for 10 volunteers for the current phase.
Official trial title: A Proof-of-concept Clinical Trial Assessing the Safety of the Coordinated Undermining of Survival Paths by 9 Repurposed Drugs Combined With Metronomic Temozolomide (CUSP9v3 Treatment Protocol) for Recurrent Glioblastoma
1What's a trial
4Get in touch
What's a trial
Not sure you're well informed about clinical trials? Learn more about their benefits, risks and other important details.
Enter your details like condition, age, gender and other preferences and we will show you a list of all relevant clinical trials.
Review the summary of the selected clinical trial and all the locations near you in order to see if it's of interest to you.
Get in touch
You've found an interesting trial? We'll need a bit more information about you so we can connect you to the doctor in charge.
Thank you for applying!
We'll contact you soon with more information.
Consult your doctor?
Some people want to consult their doctor before considering participation in a clinical trial. This is absolutely normal as your doctor should know your medical history and should be able to advise you. If you want you can easily share the information for this trial with your doctor by clicking on the button below.